Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema



Status:Recruiting
Conditions:Cardiology, Ocular
Therapuetic Areas:Cardiology / Vascular Diseases, Ophthalmology
Healthy:No
Age Range:18 - 80
Updated:11/30/-0001
Start Date:September 2012
Contact:Kevin Peters, MD
Phone:Aerpio Therapeutics

Use our guide to learn which trials are right for you!

Phase 1b/2a Open Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28 Day Repeat Subcutaneous Doses of AKB-9778 in Subjects With Diabetic Macular Edema


The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and
pilot efficacy of multiple ascending dose levels of AKB-9778 given as subcutaneous
injections daily for 28 days in patients with diabetic macular edema (DME).


Inclusion Criteria:

The following is an abbreviated list of inclusion criteria:

- Adults between 18 to 80 years of age, inclusive

- Diagnosis of diabetes mellitus (type 1 or type 2)

- Decrease in vision determined to be primarily the result of DME in the study eye

- Definite Retinal thickening due to diffuse DME involving the center of the macula in
the study eye

- Mean central subfield thickness of at least 325 µm by OCT in the study eye

- Early Treatment Diabetic Retinopathy Study (ETDRS) letter score BCVA ≤ 70 (20/40) in
the study eye

Exclusion Criteria:

The following is an abbreviated list of exclusion criteria:

- Hemoglobin A1C (HbA1C) ≥ 11.5%

- History of any of the following in the study eye (however, the following are not
exclusionary in the fellow eye):

1. Panretinal scatter photocoagulation (PRP) or focal laser within 12 weeks prior
to Screening

2. Prior pars plana vitrectomy within 12 weeks prior to Screening

3. Any ocular surgery within 12 weeks prior to Screening

4. YAG capsulotomy within 7 days prior to Screening

5. Prior intravitreal, subtenon, or periocular steroid therapy within 3 months
prior to Screening or prior treatment with intravitreal anti-VEGF treatment
within 1 month of Screening
We found this trial at
6
sites
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Ashville, NC
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials